X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Patent (212) 212
Journal Article (153) 153
Conference Proceeding (11) 11
Newspaper Article (8) 8
Publication (4) 4
Book Chapter (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
electricity (211) 211
basic electric elements (208) 208
electric solid state devices not otherwise provided for (208) 208
semiconductor devices (208) 208
humans (87) 87
female (72) 72
male (72) 72
oncology (72) 72
middle aged (64) 64
aged (61) 61
physics (60) 60
index medicus (58) 58
adult (53) 53
chemotherapy (52) 52
information storage (52) 52
static stores (52) 52
lung neoplasms - drug therapy (36) 36
carcinoma, non-small-cell lung - drug therapy (33) 33
antineoplastic combined chemotherapy protocols - therapeutic use (27) 27
lung neoplasms - pathology (27) 27
cancer (26) 26
mutation (26) 26
treatment outcome (25) 25
aged, 80 and over (24) 24
gefitinib (23) 23
lung cancer (22) 22
care and treatment (21) 21
neoplasm staging (20) 20
carcinoma, non-small-cell lung - pathology (18) 18
lung cancer, non-small cell (18) 18
adenocarcinoma (17) 17
lung neoplasms - genetics (17) 17
lung neoplasms - mortality (17) 17
carcinoma (16) 16
erlotinib (16) 16
respiratory system (16) 16
retrospective studies (16) 16
survival analysis (16) 16
nasopharyngeal carcinoma (15) 15
survival (15) 15
antineoplastic agents - therapeutic use (14) 14
carcinoma, non-small-cell lung - mortality (14) 14
clinical trials (14) 14
disease-free survival (14) 14
nsclc (14) 14
tumors (14) 14
carcinoma, non-small-cell lung - genetics (13) 13
survival rate (13) 13
analysis (12) 12
hematology, oncology and palliative medicine (12) 12
therapy (12) 12
cell lung-cancer (11) 11
cisplatin (11) 11
cisplatin - administration & dosage (11) 11
deoxycytidine - analogs & derivatives (11) 11
epidermal growth factor receptors (11) 11
nasopharyngeal neoplasms - drug therapy (11) 11
prognosis (11) 11
radiotherapy (11) 11
research (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
combined modality therapy (10) 10
docetaxel (10) 10
epidermal growth factor (10) 10
gemcitabine (10) 10
nasopharyngeal neoplasms - pathology (10) 10
non-small cell lung cancer (10) 10
patients (10) 10
protein kinase inhibitors - therapeutic use (10) 10
quinazolines - therapeutic use (10) 10
tyrosine (10) 10
cancer therapies (9) 9
carboplatin (9) 9
disease progression (9) 9
mutations (9) 9
open-label (9) 9
receptor, epidermal growth factor - genetics (9) 9
vinblastine - analogs & derivatives (9) 9
1st-line treatment (8) 8
carcinoma, squamous cell - drug therapy (8) 8
chemoradiotherapy (8) 8
clinical-trials (8) 8
deoxycytidine - administration & dosage (8) 8
genetic aspects (8) 8
kaplan-meier estimate (8) 8
lung neoplasms - metabolism (8) 8
metastasis (8) 8
non-small cell lung carcinoma (8) 8
smoking (8) 8
follow-up studies (7) 7
immunology (7) 7
multicenter (7) 7
multidisciplinary sciences (7) 7
nasopharyngeal cancer (7) 7
pharmacology & pharmacy (7) 7
protein-tyrosine kinase (7) 7
resistance (7) 7
tyrosine kinase inhibitors (7) 7
vinblastine - administration & dosage (7) 7
adenocarcinoma - drug therapy (6) 6
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 577 - 589
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 5, pp. 528 - 538
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 05/2013, Volume 105, Issue 9, pp. 595 - 605
Background The epidermal growth factor receptor (EGFR) signaling pathway is crucial for regulating tumorigenesis and cell survival and may be important in the... 
TYROSINE KINASE INHIBITORS | PHASE-III TRIAL | 1ST-LINE TREATMENT | GEFITINIB | ONCOLOGY | CLINICAL-TRIALS | 2ND-LINE TREATMENT | OPEN-LABEL | NEVER-SMOKERS | ERLOTINIB | CHEMOTHERAPY | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Cisplatin - administration & dosage | Female | Quinazolines - administration & dosage | Deoxycytidine - administration & dosage | Carcinoma, Non-Small-Cell Lung - metabolism | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Randomized Controlled Trials as Topic | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Survival Analysis | Glutamates - administration & dosage | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Deoxycytidine - analogs & derivatives | Guanine - administration & dosage | Protein-Tyrosine Kinases - antagonists & inhibitors | Usage | Gene mutations | Analysis | Patient outcomes | Physiological aspects | Development and progression | Genetic aspects | Research | Lung cancer, Non-small cell | Meta-analysis | Survival analysis | Medical research | Lung cancer
Journal Article
Journal Article
Nature, ISSN 0028-0836, 05/2018, Volume 557, Issue 7706, pp. 575 - 579
Various forms of immunotherapy, such as checkpoint blockade immunotherapy, are proving to be effective at restoring T cell-mediated immune responses that can... 
HETEROGENEITY | RESPONSES | IMMUNOTHERAPY | LANDSCAPE | MULTIDISCIPLINARY SCIENCES | NEOANTIGENS | PD-1 | ANTITUMOR | EXHAUSTION
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2005, Volume 353, Issue 2, pp. 123 - 132
Journal Article
Nature Medicine, ISSN 1078-8956, 04/2012, Volume 18, Issue 4, pp. 521 - 528
Tyrosine kinase inhibitors (TKIs) elicit high response rates among individuals with kinase-driven malignancies, including chronic myeloid leukemia (CML) and... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, RESEARCH & EXPERIMENTAL | APOPTOSIS | GEFITINIB | BIOCHEMISTRY & MOLECULAR BIOLOGY | EYE DISEASES | CHRONIC MYELOID-LEUKEMIA | CELL BIOLOGY | CELL LUNG-CANCER | FACTOR RECEPTOR EGFR | GROWTH | ACTIVATING MUTATIONS | MUTANT EGFR | Enzyme-Linked Immunosorbent Assay - methods | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Follow-Up Studies | Apoptosis - drug effects | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | BH3 Interacting Domain Death Agonist Protein - genetics | Dose-Response Relationship, Drug | Protein Isoforms - metabolism | Transfection | Bcl-2-Like Protein 11 | Statistics, Nonparametric | Aged, 80 and over | Apoptosis Regulatory Proteins - genetics | Adult | Female | Gene Expression Regulation, Neoplastic - drug effects | Lung Neoplasms - genetics | Annexins - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Membrane Proteins - genetics | Gene Frequency | Exons - genetics | Genotype | Proto-Oncogene Proteins - genetics | International Cooperation | Drug Resistance, Neoplasm - genetics | Cell Line, Tumor | Polymorphism, Genetic - genetics | Aged | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Cohort Studies | Drug Resistance, Neoplasm - drug effects | Protein Isoforms - genetics | RNA, Small Interfering - metabolism | Sequence Deletion - genetics | Antimitotic agents | Physiological aspects | Protein tyrosine kinase | Dosage and administration | Genetic aspects | Research | Antineoplastic agents | Tumor proteins | Genetic polymorphisms | Inhibitor drugs | Mutation | Kinases | Gene expression | Apoptosis | Polymorphism
Journal Article